Related Experiment Video

Updated: Mar 15, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

Geetika Bhatt1, Kami Maddocks1, Beth Christian2

  • 1The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA.

Current Hematologic Malignancy Reports
|September 11, 2016
PubMed

Insights

Antibody-drug conjugates (ADCs) offer targeted cancer therapy. Brentuximab vedotin, an ADC targeting CD30, shows promise for treating Hodgkin lymphoma and other B cell lymphomas with improved efficacy and reduced toxicity.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Cancer therapeutics have evolved towards targeted inhibition.
  • Antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic agents for targeted delivery.
  • This approach aims to enhance efficacy and minimize toxicity by localizing cytotoxic agents to target cells.

Purpose of the Study:

  • To review the therapeutic target CD30 in cancer treatment.
  • To discuss the development and clinical activity of brentuximab vedotin, an ADC.
  • To evaluate the role of brentuximab vedotin in Hodgkin lymphoma and other B cell lymphomas.

Main Methods:

  • Literature review of ADCs and CD30-targeted therapies.
  • Analysis of preclinical and clinical studies on brentuximab vedotin.
  • Focus on clinical activity and safety profiles in relevant hematologic malignancies.

Main Results:

  • CD30 is a validated therapeutic target in specific lymphomas.
  • Brentuximab vedotin has demonstrated significant clinical activity in Hodgkin lymphoma.
  • The ADC shows efficacy in certain types of B cell lymphomas, with a manageable toxicity profile.

Conclusions:

  • ADCs represent a significant advancement in cancer therapy.
  • Brentuximab vedotin is an effective treatment option for CD30-positive lymphomas.
  • Targeted therapy with brentuximab vedotin offers a favorable risk-benefit balance for patients.
Keywords:
Antibody-drug conjugateBrentuximab vedotinHodgkin lymphomaNon-Hodgkin lymphoma

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.1K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K